## Labcorp acquires assets of BioReference lab testing business

March 28, 2024—<u>Labcorp</u> and <u>Opko Health</u> announced they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of Opko, for \$237.5 million.

Labcorp will acquire BioReference's clinical diagnostics and reproductive and women's health laboratory testing businesses across the United States, with the exception of New York and New Jersey. The transaction includes patient service centers and certain customer contracts and operating assets. BioReference will continue to offer oncology and urology diagnostic services and will maintain its full operations in New York and New Jersey.

The transaction is anticipated to close in the second half of this year.